GEN Exclusives

More »

The Lists

More »
Mar 3, 2014

The Top 25 Best-Selling Drugs of 2013

Find out how many billions these blockbusters raked in.

The Top 25 Best-Selling Drugs of 2013

These therapeutics didn’t bring in less than $3 billion last year. [© grandeduc - Fotolia.com]

  • What is a best-selling drug worth? In 2013, at least, it came down to at least $3 billion in annual sales—triple the $1 billion benchmark that has long defined “blockbuster” treatments.

    Even then, $3 billion only gets your drug on the bottom of GEN’s top 25 best-selling drugs list for 2013. Among the top three disease categories, six best-selling drugs have indications for forms of cancer, four for arthritis, and three for diabetes. Four indications—asthma/COPD, heart disease, HIV, and neurological—are each represented on the list by two best sellers.

    This year’s list ranks drugs based on sales or revenue reported by biopharma companies in press announcements, annual reports, investor materials, and conference calls during 2013. Each drug is listed by name, sponsor(s), diseases indicated, 2013 sales, 2012 sales, the percentage change between both years, and fourth-quarter figures for 2013 and 2012. The patent cliff knocked out from this year’s list three best sellers of 2012—Plavix (#11, Sanofi and Bristol-Myers Squibb), Lipitor (#15, Pfizer), and Singulair (#17, Merck & Co.).

  • #25. Avonex (interferon beta-1a)

    Sponsor(s): Biogen Idec

    Indication(s): Relapsing forms of MS, to slow accumulation of physical disability and decrease frequency of clinical exacerbations

    2013 sales: $3.005 billion

    2012 sales: $2.913 billion

    % Change: 3.2%

    Q4 2013 sales: $751 million, down 0.3% from $753 million in Q4 2012

  • #24. NovoLog / NovoRapid (Insulin aspart [rDNA origin] injection)

    Sponsor(s): Novo Nordisk

    Indication(s): Man-made insulin for diabetes in adults and children

    2013 sales: $3.101 billion (DKK 16.848 billion)

    2012 sales: $2.888 billion (DKK 15.693 billion)

    % Change: 7.4%

    Q4 2013 sales: N/A

  • #23. Truvada (emtricitabine and tenofovir disoproxil fumarate)

    Sponsor(s): Gilead Sciences

    Indication(s): HIV-1 infection in adults and pediatric patients 12 years of age and older (with other antiretroviral agents); pre-exposure prophylaxis to reduce risk of sexually-acquired HIV-1 in high-risk adults (with safer sex practices)

    2013 sales: $3.135 billion

    2012 sales: $3.181 billion

    % Change: -1.4%

    Q4 2013 sales: $814 million, down 2.3% from $833 million in Q4 2012

  • #22. Symbicort (budesonide and formoterol)

    Sponsor(s): AstraZeneca

    Indication(s): Asthma untreatable via long-term asthma control medicine, or severe, in patients aged 12+; COPD, including chronic bronchitis and emphysema, in adults

    2013 sales: $3.483 billion

    2012 sales: $3.194 billion

    % Change: 9.0%

    Q4 2013 sales: $976 million, up 16.3% from $839 million in Q4 2012

  • #21. Diovan (Valsartan) and Co-Diovan (Valsartan and hydrochlorothiazide)

    Sponsor(s): Novartis

    Indication(s): Hypertension, heart failure, and postmyocardial infarction (Diovan); hypertension in patients not adequately controlled with monotherapy, and as initial therapy in patients likely to need multiple drugs (Co-Diovan)

    2013 sales: $3.524 billion

    2012 sales: $4.417 billion

    % Change: -20.2%

    Q4 2013 sales: $843 million, down 15.0% from $992 million in Q4 2012

  • #20. Atripla (efavirenz, emtricitabine, and tenofovir)

    Sponsor(s): Gilead Sciences and Bristol-Myers Squibb1

    Indication(s): HIV-1 infection in adults and children 12 years and older, alone or with other antiretroviral agents

    2013 sales: $3.648 billion1

    2012 sales: $3.574 billion1

    % Change: 2.1%

    Q4 2013 sales: $934 million, up 1.9% from $917 million in Q4 2012

  • #19. Nexium (esomeprazole)

    Sponsor(s): AstraZeneca

    Indication(s): Erosive esophagitis; gastroesophageal reflux disease (GERD); NSAID-associated gastric ulcers in at-risk patients

    2013 sales: $3.872 billion

    2012 sales: $3.944 billion

    % Change: -1.8%

    Q4 2013 sales: $0.991 billion, down 5.3% from $1.047 billion in Q4 2012

  • #18. Prevnar

    Sponsor(s): Pfizer

    Indication(s): Diseases caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in children ages six weeks through 17 years; prevention of otitis media caused by strains 4, 6B, 9V, 14, 18C, 19F, and 23F in children six weeks through five years; prevention of pneumococcal pneumonia and invasive disease caused by the 13 vaccine strains in adults ages 50 and older

    2013 sales: $3.974 billion

    2012 sales: $4.117 billion

    % Change: -3.5%

    Q4 2013 sales: $1.189 billion, up 9.2% from $1.089 billion in Q4 2012

  • #17. Januvia (sitagliptin)

    Sponsor(s): Merck & Co.

    Indication(s): Type 2 diabetes in adults

    2013 sales: $4.004 billion

    2012 sales: $4.086 billion

    % Change: -2.0%

    Q4 2013 sales: $1.121 billion, down 1.1% from $1.134 billion in Q4 2012

  • #16. Revlimid (lenalidomide)

    Sponsor(s): Celgene

    Indication(s): Multiple myeloma (with dexamethasone) for patients with at least one prior therapy; transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; mantle cell lymphoma in patients whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

    2013 sales: $4.280 billion

    2012 sales: $3.767 billion

    % Change: 13.6%

    Q4 2013 sales: $1.136 billion, up 13.4% from $1.002 billion in Q4 2012

  • #15. Copaxone

    Sponsor(s): Teva Pharmaceutical Industries

    Indication(s): Relapsing forms of multiple sclerosis

    2013 sales: $4.328 billion

    2012 sales: $3.996 billion

    % Change: 8.3%

    Q4 2013 sales: $1.142 billion, up 7.8% from $1.059 billion in Q4 2012

  • Are you taking or have you ever taken any of the drugs on our list of the best-selling drugs of 2013?



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?